



MARYLAND DEPARTMENT OF HEALTH  
Medicaid Pharmacy Program

# ADVISORY

No. 194

February 14, 2019

## **Brand vs Generic (DAW 6) Changes on Maryland Medicaid's Preferred Drug List**

**The Maryland Medicaid Pharmacy Program (MMPP) wants to alert you to the following DAW 6 changes:**

**Effective Friday, February 15, 2019:**

- Brand Parnate® tablets will no longer be preferred over its generic equivalent (tranylcypromine sulfate tablets). Claims for tranylcypromine sulfate tablets will be handled in the same manner as claims for other multisource medications. Claims for brand Parnate® will not adjudicate as the manufacturer no longer participates in the Medicaid Drug Rebate Program and therefore, as required by Federal law, cannot be covered by MMPP.
- Brand ProAir® HFA Inhalation Aerosol is preferred over its generic equivalent (albuterol sulfate inhalation aerosol). Claims for brand ProAir® HFA Inhalation Aerosol must be submitted with DAW 6 code and will be priced appropriately. An MDH Medwatch form will not be required. Claims with any other DAW code will reject.

**Effective Friday, February 22, 2019:**

- MMPP will cover brand Sabril® Tablets\* over its generic equivalent (vigabatrin tablets). Claims for brand Sabril® tablets must be submitted with DAW 6 and will be priced appropriately. Claims for Sabril® tablets with any other DAW code will reject. A MDH Medwatch form will not be required.

In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Maryland Department of Health (MDH), **Maryland Medicaid Pharmacy Program (MMPP)** has developed the **Maryland Medicaid Pharmacy Program Advisory**.

To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations.

It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via MDH, please contact the MMPP representative at 410-767-1455.

**\*Please note that Sabril® Tablets is still a non-preferred drug and will require a prior authorization by the prescriber.**

Please refer to our website for a complete list of preferred and non-preferred medications known as the Preferred Drug List (PDL) which can be found at the following link:

<https://mmcp.health.maryland.gov/pap/docs/Maryland%20PDL%201.1.19.pdf>

All Advisories are available online on MDH's web link at:

<https://mmcp.health.maryland.gov/pap/Pages/Provider-Advisories.aspx>